Clinical trials: Advanced Dedifferentiated Liposarcoma
Well-differentiated/Dedifferentiated Liposarcoma
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma. "Funding Source - FDA OOPD"
- Trial name
- NCT04438824
- Testing
- INCMGA00012, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Uveal Melanoma, Melanoma
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
- Conditions
- Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
- Trial name
- NCT05607095
- Testing
- Lifileucel (LN-144/LN-145)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated
A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
The purpose of this study is to determine whether ribociclib are effective and safe in the treatment of progressive well/dedifferentiated liposarcoma (WDL/DDL).
- Conditions
- Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated, Liposarcoma; Mixed Type, Soft-Tissue Sarcoma
- Trial name
- NCT03096912
- Testing
- Ribociclib
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Assaf-Harofeh Medical Center
Liposarcoma, Dedifferentiated
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2.
- Trial name
- NCT06058793
- Testing
- Brigimadlin
- Where
- 56 sites in United States, Argentina and 5 more
- Volunteers
- 138 people
- Sponsor
- Boehringer Ingelheim
Liposarcoma, Dedifferentiated
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Study SPH4336-US-01 is an open-label (no placebo), multicenter clinical trial to evaluate the safety, blood levels (pharmacokinetics) and preliminary anti-tumor effects of SPH4336, a selective enzyme blocker, in patients with…
- Trial name
- NCT05580588
- Testing
- SPH4336
- Where
- 9 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shanghai Pharma Biotherapeutics USA Inc.
Liposarcoma, Leiomyosarcoma
Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
This is an Italian, multicentre, single arm, phase II study, with an intra-patient comparison end point. This study aims at confirming the activity of the drug trabectedin as second/further line treatment in retroperitoneal…
- Trial name
- TRAVELL (NCT02247544)
- Testing
- Trabectedin
- Where
- 21 sites in Italy
- Volunteers
- 105 people
- Sponsor
- Italian Sarcoma Group
Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma.
- Conditions
- Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma
- Trial name
- NCT06843967
- Testing
- Mirdametinib, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to…
- Conditions
- Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Trial name
- NCT05694871
- Testing
- Palbociclib, Cemiplimab, Magnetic Resonance Imaging
- Where
- 194 sites in United States
- Volunteers
- 77 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Tumors, Sarcoma
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib. This is a Phase 1, open-label, dose-escalation, dose-expansion, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum…
- Conditions
- Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT03604783
- Testing
- TP-1287
- Where
- 10 sites in United States
- Volunteers
- 74 people
- Sponsor
- Sumitomo Pharma America, Inc.
Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with sarcoma that has spread from the primary site to other parts of the body (metastatic) or cannot be removed by…
- Conditions
- Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma
- Trial name
- NCT02500797
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 651 sites in United States
- Volunteers
- 164 people
- Sponsor
- National Cancer Institute (NCI)
Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
Liposarcomas are soft tissue sarcomas most frequent. We distinguish three subtypes on the basis of their histological and cytogenetic characteristics: well-differentiated liposarcoma / dedifferentiated, myxoid liposarcoma and /…
- Trial name
- APLIPO (NCT01876043)
- Testing
- plitidepsin
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut Bergonié
Dedifferentiated Liposarcoma
Selinexor in Advanced Liposarcoma
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma.
- Trial name
- SEAL (NCT02606461)
- Testing
- Selinexor
- Where
- 71 sites in United States, Belgium and 8 more
- Volunteers
- 342 people
- Sponsor
- Karyopharm Therapeutics Inc
Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)
First-line Treatment of Advanced/unresectable DDLPS
Evaluating the efficacy and safety of liposomal doxorubicin hydrochloride and apatinib in combination with camrelizumab for the first-line treatment of advanced/unresectable dedifferentiated liposarcoma
- Trial name
- NCT06694324
- Testing
- Liposomal Doxorubicin (Doxil), Apatinib, Camrelizumab
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Fudan University
Sarcoma, Advanced Sarcoma
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.
- Conditions
- Sarcoma, Advanced Sarcoma, High Grade Sarcoma, Leiomyosarcoma
- Trial name
- NCT04242238
- Testing
- DCC-3014, Avelumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Soft Tissue Sarcoma
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
This is a two center, 2 arm, Phase II study evaluating the combination of Ribociclib and Everolimus in patients with advanced DDL and LMS who have had at least 1 prior systemic therapy.
- Trial name
- NCT03114527
- Testing
- Ribociclib, Everolimus
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Fox Chase Cancer Center
Advanced Solid Tumors
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.
- Trial name
- NCT05944224
- Testing
- SPH4336, Cadonilimab
- Where
- 16 sites in China
- Volunteers
- 63 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Dedifferentiated Liposarcoma
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.
- Trial name
- NCT00969917
- Testing
- IPI-504
- Where
- United States
- Sponsor
- Infinity Pharmaceuticals, Inc.
Leiomyosarcoma, Liposarcoma
ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma (LPS) and leiomyosarcoma (LMS).
- Trial name
- ATX-101 (NCT05116683)
- Testing
- ATX-101
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Benjamin Izar
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Liposarcoma, Dedifferentiated
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not receiving any other cancer treatment can participate.
- Trial name
- NCT05218499
- Testing
- Brigimadlin, Doxorubicin
- Where
- 109 sites in United States, Australia and 20 more
- Volunteers
- 400 people
- Sponsor
- Boehringer Ingelheim